Emmy-Award Winning TV Host
Multiple Sclerosis Patient
In 1999, Emmy Award-winning TV personality Montel Williams was diagnosed with Multiple Sclerosis (MS). Shortly after being diagnosed, Williams established the Montel Williams MS Foundation to further the scientific study of MS, provide financial assistance to select organizations and institutions conducting research, raise national awareness, and educate the public – granting more than $1.5 million to research initiatives.
Hear from Montel on Day Two of Life Sciences Future as he discusses his life-altering experience with a medical device being developed by Helius Medical Technologies – a Pennsylvania-based life sciences company.
President and Chief Executive Officer
Director, The Wistar Institute Cancer Center
Robert and Penny Fox Distinguished Professor
Dario C. Altieri, M.D., is President and Chief Executive Officer (CEO) of The Wistar Institute, the nation’s first independent research institution devoted solely to biomedical science and a world leader in cancer, immunology, virology and infectious disease research.
Dr. Altieri joined Wistar in 2010 as Director of its National Cancer Institute (NCI)- designated Cancer Center, a position he continues to hold, and was the Institute’s first chief scientific officer. In 2015, he was appointed President and CEO. Altieri is also the Robert and Penny Fox Distinguished Professor.
Director of Public Affairs, PhRMA
Caitlin Carroll is a Director of Public Affairs for the Pharmaceutical Research and Manufacturers of America (PhRMA) where she focuses on state communications. Prior to joining PhRMA, she spent three and a half years on Capitol Hill working for the Republican Study Committee, the largest caucus in Congress, and the House Oversight and Government Reform Committee.
Head of R&D and Acting CMO, Geistlich Pharma
James C. Costin, M.D. is currently a R&D consultant to Geistlich Pharma and serves as the medical advisor to The Silverman Foundation, a philanthropic foundation that supports stem cell research projects. He obtained his MD degree from Emory University School of Medicine and competed his house officer and cardiology training at Yale University School of Medicine where he was on the full time cardiology faculty before joining the pharmaceutical industry. He was formerly Executive Vice President of Clinical and Medical Affairs and Chief Medical Officer at Perosphere, Inc. in Danbury, CT, USA. Prior to Perosphere, he was Corporate Vice President of Medical and Scientific Affairs at Carter-Wallace and was also at ICI Americas prior to that. He has worked on the research and development of numerous drugs including Tenormin (atenolol), Felbatol (felbamate), and Astelin (azelastine). He oversaw the clinical development of ciraparantag at Perosphere, which is a reversal agent for factor Xa and IIa oral anticoagulants, unfractionated and low molecular weight heparins, and fondaparinux. He lives in Lower Gwynedd, PA.
Chief Medical Officer, Egalet Corporation
Dr. Jeffrey Dayno joined Egalet as its chief medical officer in July 2014. He spent ten years in clinical and academic medicine before moving into the pharmaceutical industry. He served as vice president, global medical affairs at ViroPharma, Inc., from August 2011 to May 2014. Prior to joining ViroPharma, Dr. Dayno was the chief medical officer at Labopharm, Inc., a drug delivery technology company based in Montreal, Canada, where he first started working in the field of abuse-deterrent opioid product development. Before Labopharm, he was vice president of medical affairs at Cephalon, Inc., from 2005 to 2010. Dr. Dayno started his career in the pharmaceutical industry in 1998 at Merck & Co., Inc., where he spent 7 years in positions of increasing responsibility in the medical and scientific affairs division. Before moving into leadership roles in the pharmaceutical and biotechnology industry, he held a number of clinical appointments, including assistant professor of neurology, Jefferson Medical College, and medical director of the Jefferson Health System Stroke Center Network. Dr. Dayno earned his medical degree from Temple University School of Medicine, completed a fellowship in stroke and cerebrovascular disorders in the Department of Neurology at Henry Ford Hospital, a National Institutes of Health (NIH) Clinical Research Center for stroke and headache, and was board certified in neurology. Dr. Dayno is currently a member of the Board of Visitors of Temple University School of Medicine and was a former chairman of the Philadelphia Stroke Council.
President, Chief Executive Officer and Chairman of the Board of Directors, Helius Medical Technologies
Phil joined Helius Medical Technologies in 2013. He has more than 28 years of experience in pharmaceutical and healthcare commercialization gained at Bristol Myers Squibb (BMS) and as CEO of GSW Worldwide and, later, at MediMedia Health. Before joining Helius, Phil led MediMedia Health Marketing Services, where he was responsible for strategic development, nurturing the company’s clients and developing nonpersonal products and services in the healthcare industry. As GSW’s president and CEO, Phil was responsible for worldwide operations in 15 major global markets and a turnover of $160 million with 700 employees globally. His primary work included global marketing, commercialization and new business model development for pharmaceutical, device and diagnostics companies.
Executive Vice Dean and Chief Scientific Officer
William Wikoff Smith Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Dr. Epstein graduated from Harvard College in 1983, Harvard Medical School in 1988 and completed his Residency and Fellowship in Medicine and Cardiology at the Brigham and Women’s Hospital, where he also completed an HHMI Postdoctoral Fellowship in Genetics. In 1996 he accepted a position as Assistant Professor of Medicine in the Division of Cardiology at the University of Pennsylvania. From 2006-2015, he served as Chairman of the Department of Cell and Developmental Biology and Scientific Director of the Penn Cardiovascular Institute. He is currently the William Wikoff Smith Professor, Executive Vice Dean and Chief Scientific Officer at the Perelman School of Medicine at the University of Pennsylvania.
Professor, Geisinger Health System
Genomic Medicine Institute & Office of the Chief Scientific Officer
Andy Faucett directs engagement and education for the MyCode® Community Health Initiative. He focuses on the return of research results, genetic testing oversight, ethical and consent issues, education, genetic counseling service delivery, patient registries, and DTC genetic testing. On the the NIH funded ClinGen project, he led the education and engagement efforts, the patient registry and CADRE, the ethical, legal and social issues aspect of ClinGen. He has a B.S. from the Baptist College at Charleston, M.S. in Human Genetics from Sarah Lawrence College, board certification from the American Board of Genetic Counseling (ABGC) and is licensed as a Genetic Counselor in Pennsylvania. He previously served on the NSGC, ABGC and NCHPEG Boards of Directors, the NSGC Public Policy Committee, and the ASHG Information and Education Committee. He held positions at Emory University School of Medicine; Baylor College of Medicine; Memorial, Savannah, GA; and the CDC prior to Geisinger.
Health and Medical Reporter / 6ABC Action News
Ali Gorman, R.N. joined Action News in March 2008 as the Health and Medical Reporter. Ali grew up in South Jersey and graduated from Eastern High School in Voorhees, New Jersey. She then went on to earn a Bachelor of Science in Nursing Degree from Georgetown University.
Ali worked as a registered nurse for several years and served as a Nurse Corps officer in the U.S. Navy before going back to school to earn her Master’s Degree at Northwestern’s Medill School of Journalism.
Senior Vice President, Head of US Business Unit, WuXi AppTec
Felix Hsu has led the WuXi AppTec U.S. Business Unit for over eight years. WuXi has provided cell therapy manufacturing since 2004, and over the last 4-5 years has invested significantly in building out manufacturing capabilities for Advanced Therapies which include cell and gene therapy. Felix’s career also includes over 20 years of experience in the medical device and pharmaceutical industries including roles as the VP for Global Supply Chain and the GM for Cardiac Surgery in Asia Pacific at Medtronic.
Head of Strategy and Operations for Cell and Gene Therapy within Rare Diseases, GSK
Jessica Imrie is Head of Strategy and Operations for Cell and Gene Therapy within Rare Diseases at GSK. In 2016, she led the European launch of a major medicine for children born with ADA Severe Combined Immunodeficiency (SCID). Today, she leads a cross-functional team to scale up the distribution of ex-vivo gene therapies in order to increase regional access of these transformative medicines to patients. Jessica has 15 years of experience within pharmaceutical industry and joined Rare Diseases in 2011 after her daughter was diagnosed with SCID. Previously, Jessica worked for Ernst & Young, New Zealand implementing business change initiatives across major hospitals.
Jessica received her MBA in healthcare and pharmaceuticals from Drexel University, Philadelphia and her undergraduate degree in Strategic Mngt and Industrial Psychology at the University of Waikato in New Zealand.
Vice President, Biopharma Collaborations & Companion Diagnostics
Kamala K. Maddali, DVM, Ph.D, is Vice President, Biopharma Collaborations and Companion Diagnostics at Cancer Genetics Inc. She joined CGI in 2015, and plays a pivotal role in the biomarker and companion diagnostics strategy in the context of pharma novel drug development programs.
Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. She has promoted the proper utilization of biomarkers, personalized medicine and diagnostics in drug development and patient management to bridge the gap between drug and diagnostic industries. She was Global Director Scientific Development -Biomarkers & Companion Diagnostics for Q2 Solutions (A Quintiles & Quest Diagnostics joint venture). She brings a lot of strategic values from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.
Chief Executive Officer, Spark Therapeutics
Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. He also serves on Spark Therapeutics’ board of directors.
Chief Financial Officer, AdaptImmune
Adrian Rawcliffe has served as our Chief Financial Officer since March 2015 and leads our financial strategy and operations, as well as Investor Relations, corporate communications, global IT and facilities. He has 17 years of experience within the pharmaceutical industry and most recently served as Senior Vice President, Finance of GSK’s North American Pharmaceuticals business. Mr. Rawcliffe currently serves as a non-executive director of WAVE Life Sciences (NASDAQ: WVE).
Former Chairman of National Transportation Safety Board; Transportation & Safety Analyst for CBS News
When a plane crash captivates the nation, Mark Rosenker is one of the few people who can claim an informed understanding of what went wrong and what could have been done to prevent it. As two-time chairman of the National Transportation Safety Board (NTSB), he led the investigations that follow any civil aviation accident in the nation, as well as significant accidents involving highway, railroad, marine, and pipeline. It is a stressful role, but Rosenker calls his time at the NTSB “the best job I ever had” because of the opportunity to recommend and implement safety regulations that save lives and prevent more accidents from happening. A compelling storyteller, Rosenker uses his background with the NTSB to present an insider’s perspective on current safety precautions for the aviation, automobile, and railroad industries.
Associate Vice Provost for Research
Executive Director, Penn Center for Innovation (PCI)
University of Pennsylvania
John S. Swartley, MBA, PhD is Associate Vice Provost for Research and the Executive Director of the Penn Center for Innovation (PCI) at the University of Pennsylvania (Penn). He leads a multi-faceted team that focuses on facilitating new product development, corporate partnerships and alliances, and new venture creation based on expertise and technologies created at Penn. Prior to joining Penn in 2007, Dr. Swartley served as Senior Vice President and General Partner of BCM Technologies (BCMT), the venture capital investment subsidiary of Baylor College of Medicine. Dr. Swartley joined BCMT in 2003 from the Yale University Office of Cooperative Research where he was Associate Director of the Medical Campus Office. Over his career, Dr. Swartley has negotiated hundreds of commercialization and research partnership agreements and has participated in the formation and oversight of dozens of university spin-out companies that have collectively raised more than a billion dollars of investment capital. He holds a B.S. in Biology from Bates College, an MBA from the Goizueta School of Business at Emory University, and a PhD in Microbial & Molecular Genetics from Emory University.
President & CEO, University City Science Center
Steve Tang became President and CEO of the University City Science Center, the nation’s oldest and largest urban research park, in 2008. Dr. Tang is the first president in the Science Center’s history to have not only led a company through venture funding and an initial public offering, but to also serve as a senior executive with a large life sciences company as it acquired and integrated smaller start‐ups. In September 2016, Dr. Tang was re‐appointed to the National Advisory Council on Innovation and Entrepreneurship (NACIE) and now serves as NACIE co‐chair through 2018. NACIE members offer recommendations to the U.S. Secretary of Commerce for policies and programs designed to make U.S. communities, businesses, and the workforce more globally competitive. Previously, Tang served on the U.S. Department of Commerce’s Innovation Advisory Board.
CEO and Chairman, CloudMine
Stephen Wray has over 35 years of experience in healthcare communications innovation and entrepreneurial leadership, including his current role as CEO and Chairman of CloudMine, a Philadelphia-based, privately-funded health cloud platform provider. Previously, Steve served as CEO and Chairman of Cadient Group, which was acquired by Cognizant in 2014, and CEO of MNG Direct, a privately-backed marketing automation platform for life sciences. During his career, Steve has also held executive leadership positions as North American President for Ogilvy Healthworld (a WPP company), and Vice President of Marketing Communications for Wyeth (now Pfizer). Steve is a past recipient of the Ernst and Young Entrepreneur of the Year Award, and was named the 2014 Philadelphia Main Line CEO of the Year by the Philadelphia Main Line Chamber of Commerce. Active in numerous philanthropic efforts, Steve is a regional angel investor, board member and a visiting professor for local academic programs, Steve has been listed among the 100 Most Influential People in the Life Sciences industry by PharmaVoice magazine. Most recently, Steve and the CloudMine team were recognized by Philadelphia Business Journal with the Healthcare Innovator Award for 2017.